

Claims

- 1) Bacterium of the genus *Salmonella* that in its wild type form carries flagella, said bacterium not being capable to induce antibodies against at least one antigenic determinant of flagellin or flagella, for use in a vaccine for the protection of humans or animals against Salmonellosis.
- 2) Bacterium according to claim 1, wherein said bacterium is not capable to induce antibodies against at least one antigenic determinant of flagellin or flagella due to a mutation in a gene of the flagellar biogenesis pathway.
- 3) Bacterium according to claim 2, wherein said mutation is located in the flagellin gene.
- 4) Bacterium according to claims 1-3, wherein said bacterium is selected from the group consisting of *S. typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *typhi*, *abortus-ovi*, *abortus-equi*, *paratyphi A and B*, *derby*, *hadar*, *heidelberg*, *agona* and *arizonae*.
- 5) Bacterium according to claim 1-4, wherein said bacterium further carries a heterologous gene, said heterologous gene preferably being inserted in the flagellin gene.
- 6) Bacterium according to claim 1, characterised in that it belongs to a strain of which an example has been deposited with the Centraalbureau voor Schimmelcultures under accession-number CBS 108955.
- 7) Vaccine for the protection of animals against Salmonellosis, characterised in that the vaccine comprises bacteria as defined in claims 1-6 or antigenic material thereof and a pharmaceutically acceptable carrier.

8) Vaccine according to claim 7, characterised in that said bacteria are in a live attenuated form.

5 9) Vaccine according to claim 7, characterised in that said bacteria are inactivated.

10) vaccine according to claims 7-9, characterised in that it comprises an adjuvant.

10 11) vaccine according to claims 7-10, characterised in that it is in a freeze-dried or spray-dried form.

12) Use of a bacterium as defined in claims 1-6 for the manufacture of a vaccine for the protection of humans or animals against infection with a *Salmonella* bacterium or the pathogenic effects of infection.

15

13) Method for the preparation of a vaccine according to claims 7-11, characterised in that said method comprises the admixing of a bacterium as defined in claims 1-6 or antigenic material thereof and a pharmaceutically acceptable carrier.